Predicting peritoneal carcinomatosis of gastric cancer: A simple model to exempt low-risk patients from unnecessary staging laparoscopy
- PMID: 35937608
- PMCID: PMC9349356
- DOI: 10.3389/fsurg.2022.916001
Predicting peritoneal carcinomatosis of gastric cancer: A simple model to exempt low-risk patients from unnecessary staging laparoscopy
Abstract
Background: Peritoneal carcinomatosis (PC) of gastric cancer indicates a poor outcome and is mainly diagnosed by staging laparoscopy (SL). This study was designed to develop a risk stratification model based on the number of risk factors to exempt low-risk patients from unnecessary SL.
Methods: This was a retrospective cohort study based on a single institution between January 2015 and December 2019. SL is indicated for patients of advanced locoregional stage, and clinicopathologic characteristics of 535 consecutive patients were included. PC-associated variables were identified by logistic regression analysis. A risk stratification model based on the number of risk factors was constructed, and we defined its predictive value with a receiver operating characteristic (ROC) curve and negative predictive value.
Results: In total, 15.9% of included patients were found to have PC during SL. Borrmann type IV, elevated CA125, and tumour diameter ≥5 cm were independent risk factors of PC. These three factors combined with cT4 were selected as predictive factors, and the number of predictive variables was significantly related to the possibility of PC (2.0%, 12.8%, 20.0%, 54.2%, and 100%, respectively). When the cutoff value is more than one predictive factor, the negative predictive value is 98.0%, with an area under the curve of 0.780. This model could exempt 29.8% of unnecessary SL compared to the indication of the current NCCN guideline.
Conclusions: We constructed a simple model to predict the probability of PC using the number of predictive factors. It is recommended that patients without any of these factors should be exempt from SL.
Keywords: gastric cancer; peritoneal carcinomatosis; prediction model; risk factor; staging laparoscopy.
© 2022 Li, Guan, Liu, Li, Ying, Shan and Li.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Similar articles
-
Calculation of a clinical predictive factors identifying peritoneal disease on a staging laparoscopy in gastric cancers.South Asian J Cancer. 2019 Jul-Sep;8(3):166-167. doi: 10.4103/sajc.sajc_182_18. South Asian J Cancer. 2019. PMID: 31489289 Free PMC article.
-
Risk factors associated with peritoneal carcinomatosis of gastric cancer in staging laparoscopy: A systematic review and meta-analysis.Front Oncol. 2022 Oct 28;12:955181. doi: 10.3389/fonc.2022.955181. eCollection 2022. Front Oncol. 2022. PMID: 36387230 Free PMC article.
-
A preoperative predictive tool to assess the need for staging laparoscopy in oesophagogastric cancer patients.Ann R Coll Surg Engl. 2024 Apr;106(4):369-376. doi: 10.1308/rcsann.2022.0140. Epub 2023 Aug 29. Ann R Coll Surg Engl. 2024. PMID: 37642164 Free PMC article.
-
Yield of peritoneal cytology in staging patients with gastric and gastroesophageal cancer.J Surg Oncol. 2019 Dec;120(8):1350-1357. doi: 10.1002/jso.25729. Epub 2019 Oct 14. J Surg Oncol. 2019. PMID: 31612494
-
Role of staging laparoscopy for gastric cancer patients.Ann Gastroenterol Surg. 2019 Aug 21;3(5):496-505. doi: 10.1002/ags3.12283. eCollection 2019 Sep. Ann Gastroenterol Surg. 2019. PMID: 31549009 Free PMC article. Review.
Cited by
-
Dual-energy CT quantitative parameters to evaluate occult peritoneal metastasis in advanced gastric cancer preoperatively.Abdom Radiol (NY). 2024 Oct;49(10):3309-3318. doi: 10.1007/s00261-024-04303-x. Epub 2024 Apr 18. Abdom Radiol (NY). 2024. PMID: 38634880
-
Gastric Cancer (GC) with Peritoneal Metastases (PMs): An Overview of Italian PSM Oncoteam Evidence and Study Purposes.Cancers (Basel). 2023 Jun 10;15(12):3137. doi: 10.3390/cancers15123137. Cancers (Basel). 2023. PMID: 37370747 Free PMC article. Review.
References
-
- Fujitani K, Yang H, Mizusawa J, Kim Y, Terashima M, Han S, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. (2016) 17(3):309–18. 10.1016/S1470-2045(15)00553-7 - DOI - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous